Throughout 2019, Muscular Dystrophy News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important…
Articles by Joana Carvalho, PhD
Treatment with gene therapy candidate SGT-001 may lead to clinically meaningful improvements for patients with Duchenne muscular…
The experimental therapy ATL1102 is safe and continues to show evidence of improved upper muscle strength and function in…
The U.S. Food and Drug Administration (FDA) has authorized use of the first test intended to facilitate newborn screening for…
Long-term treatment with Puldysa (idebenone) provides a stable reduction of lung function decline by approximately 50% in people…
NS Pharma will share future plans for viltolarsen, its investigational exon-skipping therapy for Duchenne muscular dystrophy (DMD)…
The clinical program evaluating the safety, tolerability, and efficacy of RG6206 in boys with Duchenne muscular dystrophy (DMD)…
Vamorolone, an experimental treatment for Duchenne muscular dystrophy (DMD) being developed by ReveraGen Biopharma, continues to improve muscle…
Vamorolone (VBP15), an experimental treatment for Duchenne muscular dystrophy (DMD) developed by ReveraGen Biopharma, improves muscle function of…
Fulcrum Therapeutics announced it has launched ReDUX4, a Phase 2b clinical trial designed to assess the safety and efficacy…